R
Rachel Legeron
Researcher at Université Bordeaux Segalen
Publications - 8
Citations - 142
Rachel Legeron is an academic researcher from Université Bordeaux Segalen. The author has contributed to research in topics: Free fraction & Prospective cohort study. The author has an hindex of 5, co-authored 8 publications receiving 99 citations.
Papers
More filters
Journal ArticleDOI
Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study
Cédric Carrié,Laurent Petit,Nicolas d'Houdain,Noemie Sauvage,Vincent Cottenceau,Mélanie Lafitte,Cecile Foumenteze,Quentin Hisz,Deborah Menu,Rachel Legeron,Dominique Breilh,François Sztark +11 more
TL;DR: In this article, the authors assessed whether augmented renal clearance (ARC) impacts negatively on antibiotic concentrations and clinical outcomes in patients treated by high-dose β-lactams administered continuously, and the performance of CLCr was assessed by a ROC curve, and multivariable logistic regression was performed to determine risk factors for subexposure and therapeutic failure.
Journal ArticleDOI
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
Boris Jung,Martin Mahul,Dominique Breilh,Rachel Legeron,Jeremy Signe,Hélène Jean-Pierre,Hélène Jean-Pierre,Anne-Catrin Uhlemann,Nicolas Molinari,Samir Jaber +9 more
TL;DR: Obese patients were more likely than nonobese patients to experience piperacillin underdosing when facing high minimal inhibitory concentration pathogens, and p Piperacillin drug monitoring might be necessary in the sickest patients who are at the highest risk of unpredictable plasma concentration exposing them to overdose, toxicity, underdoses, and treatment failure.
Journal ArticleDOI
A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.
Rachel Legeron,Fabien Xuereb,Stéphane Chaignepain,Alain-Pierre Gadeau,Stéphane Claverol,Jean-William Dupuy,Sarah Djabarouti,Thierry Couffinhal,Jean-Marie Schmitter,Dominique Breilh +9 more
TL;DR: In this paper, a liquid chromatography tandem mass spectrometry (LC-MS/MS) method was proposed to quantify the plasmatic fraction of bevacizumab in human plasma.
Journal Article
A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC–MS/MS in human plasma comparing two internal standard calibration approaches B Analytical technologies in the biomedical and life sciences
Rachel Legeron,Fabien Xuereb,Stéphane Chaignepain,Alain-Pierre Gadeau,Stéphane Claverol,Jean-William Dupuy,Sarah Djabarouti,Thierry Couffinhal,Jean-Marie Schmitter,Dominique Breilh +9 more
TL;DR: A reliable and cost-effective LC-MS/MS method to quantify total plasmatic fraction of bevacizumab in human plasma and proposed a generic methodology easily transposable to quantify all IgG1 subclass very useful for clinical pharmacokinetics studies.
Journal ArticleDOI
Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study.
Claire Roubaud Baudron,Rachel Legeron,Julien Ollivier,Fabrice Bonnet,Carine Greib,Florent Guerville,C. Cazanave,David Kobeh,Véronique Cressot,Nicolas Moneger,Marie-Neige Videau,Elise Thiel,Carine Foucaud,Aurélie Lafargue,Albane de Thezy,Jessica Durrieu,Isabelle Bourdel Marchasson,Geneviève Pinganaud,D Breilh +18 more
TL;DR: SC administration of ertapenem is an alternative to IV administration in older patients and is useful for the treatment of infections with ESBL-producing enterobacteria, as reported and compared.